| Annual · values | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -16.34 M USD | -68.92 M USD | -125.18 M USD | -124.82 M USD | -71.93 M USD | -38.31 M USD | -29.53 M USD | -19.94 M USD | -20.82 M USD |
| Depreciation & Amortization | 9.53 M USD | 14.02 M USD | 13.71 M USD | 9.62 M USD | 3.35 M USD | 1.48 M USD | 1.13 M USD | 1.32 M USD | 1.50 M USD |
| Stock-Based Compensation | 4.53 M USD | 9.74 M USD | 15.18 M USD | 22.42 M USD | 9.72 M USD | 1.55 M USD | 1.35 M USD | 1.19 M USD | 382830 USD |
| Capital Expenditures | — | — | — | — | — | 0 USD | 61056 USD | 331716 USD | 1.02 M USD |
| Cash Flow from Investing | -12.75 M USD | 73.84 M USD | 24.16 M USD | 82.77 M USD | -278.06 M USD | -2.45 M USD | -61056 USD | -331716 USD | -1.02 M USD |
| Cash Flow from Financing | 24.04 M USD | -13.69 M USD | 113.81 M USD | 23.01 M USD | 336.11 M USD | 61.90 M USD | 30.38 M USD | 35.78 M USD | 17.61 M USD |
| Dividends Paid | — | — | — | — | — | — | — | — | — |
| Stock Buybacks | — | — | — | — | — | — | — | — | — |
| Free Cash Flow | — | — | — | — | — | -38.31 M USD | -29.59 M USD | -20.28 M USD | -21.84 M USD |
Bionano Genomics develops genome analysis software that enables genomics laboratories to analyze and interpret genomic data across multiple platforms, generating comprehensive insights for research and clinical applications. The company's solutions are designed to detect genomic variations and provide a unified view of genome data, addressing critical questions in cancer diagnosis, genetic disease detection, and treatment planning. Bionano Genomics serves the genomics and clinical laboratory markets, offering tools that integrate data from various sequencing and analysis technologies. The company operates in the life sciences and healthcare technology sector, where it plays a role in advancing precision medicine and improving diagnostic capabilities for healthcare providers and research institutions worldwide.